RTP Mobile Logo
Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal Cancer
Released May 2019

Featuring perspectives from Drs Tanios Bekaii-Saab and Alan P Venook. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancers.

    OVERVIEW OF ACTIVITY
    Cancer of the colon or rectum is the fourth most frequently diagnosed cancer and the second most common cause of cancer-related death in the United States. In the year 2019, it is estimated that 145,600 people will be diagnosed with colon or rectal cancer in the United States, representing a continued decline over the past few decades thought to be related to improvements in detection and treatment.

    Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering management algorithms, and in order to offer optimal patient care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, this program features a roundtable discussion with 2 leading gastrointestinal oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES

    • Coordinate comprehensive biomarker analysis for patients diagnosed with metastatic colorectal cancer (mCRC), and use this information to guide evidence-based care.
    • Develop an understanding of the prognostic and predictive implications of tumor sidedness, and use this information to counsel patients regarding guideline-endorsed therapeutic options.
    • Consider patient and disease characteristics, including primary tumor location and potentially targetable genetic abnormalities (eg, BRAF, HER2) to inform the selection of first- and later-line therapy for mCRC.
    • Communicate the benefits and risks of approved anti-VEGF, anti-EGFR and other systemic therapies to patients with newly diagnosed and progressive mCRC, and develop an evidence-based algorithm for sequencing these available options.
    • Appraise the recent FDA approvals of nivolumab, pembrolizumab and the combination of nivolumab/ipilimumab for patients with microsatellite instability-high or mismatch repair-deficient mCRC, and appropriately integrate these agents into current nonresearch treatment algorithms.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THESE CME ACTIVITIES
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
    Vice-Chair and Section Lead, Division of Medical Oncology
    Medical Director, Cancer Clinical Research Office
    Senior Associate Consultant
    Mayo Clinic 
    Phoenix, Arizona 

    Advisory Committee: Immuneering Corporation, ImmunoGen Inc; Consulting Agreement: AbbVie Inc; Data and Safety Monitoring Board/Committee: ARMO Biosciences, Lilly, SillaJen.

    Alan P Venook, MD
    The Madden Family Distinguished Professor of
    Medical Oncology and Translational Research
    University of California, San Francisco
    Shorenstein Associate Director, Program Development
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Advisory Committee: Array BioPharma Inc, Eisai Inc, Genentech, Taiho Oncology Inc; Contracted Research: Bristol-Myers Squibb Company, Genentech; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, Halozyme Inc.

    MODERATOR Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: May 2019
    Expiration date: May 2020

Acknowledge and close

Listen to audio:
Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal Cancer
Released May 2019

Featuring perspectives from Drs Tanios Bekaii-Saab and Alan P Venook. (Audio Program)

Read print: